ATE537819T1 - Nutrazeutische zusammensetzungen zur behandlung von muskelschwund - Google Patents

Nutrazeutische zusammensetzungen zur behandlung von muskelschwund

Info

Publication number
ATE537819T1
ATE537819T1 AT06806182T AT06806182T ATE537819T1 AT E537819 T1 ATE537819 T1 AT E537819T1 AT 06806182 T AT06806182 T AT 06806182T AT 06806182 T AT06806182 T AT 06806182T AT E537819 T1 ATE537819 T1 AT E537819T1
Authority
AT
Austria
Prior art keywords
muscle wasting
treating muscle
nutraceutical compositions
muscle
nutraceutical
Prior art date
Application number
AT06806182T
Other languages
English (en)
Inventor
Daniel Raederstorff
Ying Wang-Schmidt
Swen Wolfram
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Application granted granted Critical
Publication of ATE537819T1 publication Critical patent/ATE537819T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06806182T 2005-10-14 2006-10-11 Nutrazeutische zusammensetzungen zur behandlung von muskelschwund ATE537819T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05022414 2005-10-14
EP06009943 2006-05-15
PCT/EP2006/009814 WO2007042271A2 (en) 2005-10-14 2006-10-11 Nutraceutical composition for the treatment of muscle wasting

Publications (1)

Publication Number Publication Date
ATE537819T1 true ATE537819T1 (de) 2012-01-15

Family

ID=37499262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06806182T ATE537819T1 (de) 2005-10-14 2006-10-11 Nutrazeutische zusammensetzungen zur behandlung von muskelschwund

Country Status (7)

Country Link
EP (1) EP1937232B1 (de)
JP (1) JP2009511522A (de)
KR (1) KR20080105023A (de)
CN (1) CN101978958A (de)
AT (1) ATE537819T1 (de)
ES (1) ES2379810T3 (de)
WO (1) WO2007042271A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015686A1 (en) * 2005-07-07 2007-01-18 Heuer Marvin A Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
EP1993522A2 (de) * 2005-10-26 2008-11-26 Kao Corporation Resveratrol und/oder weinblattextrakt als ausdauerverbesserer, mittel gegen alterung und muskelkraftverstärker
EP2007366A2 (de) * 2006-03-24 2008-12-31 Charles H. CELLA Tierproduktanreicherung mit resveratrol
US8962678B2 (en) 2006-07-05 2015-02-24 Kao Corporation Senescence inhibitor
EP2170338A2 (de) * 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs zur modulierung von energieregulation und gehirnfunktion
US20110112201A1 (en) * 2008-04-17 2011-05-12 Jiankang Liu Hydroxytyrosol benefits mitochondria
JP5614817B2 (ja) * 2009-04-17 2014-10-29 ディーエスエム アイピー アセッツ ビー．ブイ． ミトコンドリアの機能およびエネルギー生産を高めるためのヒドロキシチロソールの組合せ
WO2011033884A1 (ja) * 2009-09-18 2011-03-24 明治乳業株式会社 筋拘縮予防剤
EP2501371A4 (de) * 2009-10-07 2013-07-31 Dsm Ip Assets Bv Verwendung von hydroxytyrosol für verbesserte muskeldifferenzierung
WO2012036168A1 (ja) * 2010-09-14 2012-03-22 北海道公立大学法人札幌医科大学 筋ジストロフィーを処置するための組成物
ITMI20112093A1 (it) * 2011-11-17 2013-05-18 Lachifarma Srl Lab Chimico Farmaceutico Sa Composizioni comprendenti idrossitirosolo e epigallocatechin gallato
BR112015007131A2 (pt) 2012-10-04 2017-07-04 Abbott Lab métodos para melhorar o efeito de egcg em atenuar a perda muscular esquelética
US9844531B2 (en) 2013-03-15 2017-12-19 Abbott Laboratories Methods of maintaining and improving muscle function
JP6405310B2 (ja) * 2013-08-09 2018-10-17 サントリーホールディングス株式会社 ヒドロキシチロソール及びその誘導体の体内吸収促進剤及びその利用
WO2015094767A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for maintaining or increasing bodyweight using decaffeinated green tea extract
CN106061291A (zh) * 2013-12-18 2016-10-26 雅培公司 使用绿茶提取物来增加骨骼肌蛋白质合成的方法
US10751357B2 (en) * 2015-11-17 2020-08-25 Societe Des Produits Nestle S.A. Compositions and methods using a polyphenol for musculoskeletal health
WO2018224636A1 (en) * 2017-06-09 2018-12-13 Vib Vzw Glutamine dehydrogenase inhibitors for use in muscle regeneration
CN107811997A (zh) * 2017-11-10 2018-03-20 大连医科大学附属第医院 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用
CA3083052A1 (en) * 2017-11-21 2019-05-31 Societe Des Produits Nestle S.A. Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass
WO2021072450A2 (en) * 2020-03-10 2021-04-15 The Regents Of The University Of California Novel nutrients to enhance load-induced muscle hypertrophy
WO2025030001A2 (en) * 2023-08-02 2025-02-06 Abbott Laboratories Methods and compositions for maintaining skeletal muscle mobility and/or mass, and/or for recovery of skeletal muscle strength

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103211806B (zh) * 2003-05-27 2015-09-09 帝斯曼知识产权资产管理有限公司 新颖的营养药物性组合物及其用途
US20070015686A1 (en) * 2005-07-07 2007-01-18 Heuer Marvin A Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
JPWO2007020917A1 (ja) * 2005-08-18 2009-02-26 国立大学法人徳島大学 ユートロフィン産生の増強持続剤とこれを用いる加工食品

Also Published As

Publication number Publication date
WO2007042271A2 (en) 2007-04-19
WO2007042271A8 (en) 2008-08-28
EP1937232B1 (de) 2011-12-21
EP1937232A2 (de) 2008-07-02
KR20080105023A (ko) 2008-12-03
CN101978958A (zh) 2011-02-23
ES2379810T3 (es) 2012-05-03
JP2009511522A (ja) 2009-03-19
WO2007042271A3 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
ATE537819T1 (de) Nutrazeutische zusammensetzungen zur behandlung von muskelschwund
BRPI0518334A2 (pt) composiÇço de revestimento, mÉtodo de revestimento, revestimento, e, mÉtodo para preparar uma composiÇço de revestimento
CR11731A (es) Composiciones y procedimientos para su preparación y uso
SE0301010D0 (sv) Novel compounds
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
SE0301009D0 (sv) Novel compounds
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
TW200612892A (en) Novel compounds
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
BRPI0713447A2 (pt) composição forma de dosagem oral sólida, e, método para o tratamento de dor
TW200732296A (en) Novel compounds
MY148286A (en) Freeze-dried, aerated dairy or dairy-substitute compositions and methods of making thereof
AR050717A1 (es) Composiciones farmaceuticas
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
TW200621690A (en) Novel compounds
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion